A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Heart, Lung and Vascular Research -
Location
-
Principal Investigator
-
Sponsor
Acceleron
You are being asked to take part in a research study of an experimental treatment called
sotatercept. “Experimental” means that sotatercept is currently being tested and is not
approved for sale by any Health Authorities/regulatory agencies, such as the Food and Drug
Administration (FDA), in any country.
We want to find out if taking sotatercept with your current medications is safe and can help
slow the progression of Pulmonary Hypertension caused by left heart disease compared with your current
medications alone.
Enrollment Form
This study is currently enrolling.